3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
2
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Cyclophosphamide
160
Peripheral Blood Stem Cell Transplantation
85
fludarabine phosphate
81
Filgrastim
78
Methotrexate
69
Etoposide
68
Cytarabine
62
Rituximab
61
Radiotherapy
56
Cyclosporine
52
Mycophenolic Acid
51
Vincristine
50
Whole-Body Irradiation
48
Busulfan
46
Tacrolimus
41
Antilymphocyte Serum
40
Melphalan
39
Dexamethasone
39
Prednisone
36
Methylprednisolone
35
Doxorubicin
35
fludarabine
28
Granulocyte Colony-Stimulating Factor
25
Calcium Dobesilate
25
merphos
24
Leucovorin
23
Cord Blood Stem Cell Transplantation
22
sargramostim
18
dexamethasone acetate
18
dexamethasone 21-phosphate
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Burkitt Lymphoma
×
relatlimab
×
Other hematologic neoplasm
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled